Company intelligence / Profile preview

Aptinyx Inc.

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Aptinyx has had several Phase 2 clinical trials with disappointing results. NYX-458 did not demonstrate sufficient efficacy in cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies[9]. NYX-2925 did not achieve the primary endpoint in a Phase 2b study for fibromyalgia[10]. The company terminated its study of NYX-783 in PTSD to analyze available data[9].

Therapeutic areas: PsychiatryNeurologyRheumatology
Modalities: Small moleculessynthetic small molecules
Industry: Biotech

Drug pipeline

4 assets

NYX-783

3 more assets in the full pipeline.

Request access →

Partnerships

Allergan plc

Beyond the preview

Go deeper on Aptinyx Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptinyx Inc..

Explore the full profile